Nuri Jang1, Hee Jung Kwon1, Min Hui Park1, Su Hwan Kang2, Young Kyung Bae3. 1. Department of Pathology, Yeungnam University College of Medicine, Daegu, South Korea. 2. Department of Surgery, Yeungnam University College of Medicine, Daegu, South Korea. 3. Department of Pathology, Yeungnam University College of Medicine, Daegu, South Korea. ykbae@ynu.ac.kr.
Abstract
BACKGROUND: This study investigated the prognostic value of tumor-infiltrating lymphocyte (TIL) density as determined by molecular subtype and receipt of adjuvant chemotherapy in invasive breast cancer (IBC). METHODS: Stromal TIL densities were evaluated in 1489 IBC samples using recommendations proposed by the International TILs Working Group. Cases were allocated to high- and low-TIL density groups using a cutoff of 10%. RESULTS: Of the 1489 IBC patients, 427 (28.7%) were assigned to the high-TIL group and 1062 (71.3%) to the low-TIL group. High TIL density was found to be significantly associated with large tumor size (p = 0.001), high histologic grade (p < 0.001), and high Ki-67 labeling index (p < 0.001). Triple-negative and human epidermal growth factor receptor 2 (HER2)-positive subtypes had significantly higher TIL densities than luminal A or B (HER2-negative) subtypes (p < 0.001). High TIL density was significantly associated with prolonged disease-free survival (DFS) by univariate (p < 0.001) and multivariate (p < 0.001) analyses. In the low-TIL-density group, the patients who did not receive adjuvant chemotherapy showed better DFS (p < 0.001), but no such survival difference was observed in the high-TIL group (p = 0.222). For the patients who received adjuvant anthracycline, high-TIL density was found to be an independent prognostic factor of favorable DFS in the luminal B (HER2-negative; p = 0.003), HER2-positive (p = 0.019), and triple-negative (p = 0.017) subtypes. CONCLUSION: Measurements of TIL density in routine clinical practice could give useful prognostic information for the triple-negative, HER2-positive, and luminal B (HER2-negative) IBC subtypes, especially for patients administered adjuvant anthracycline.
BACKGROUND: This study investigated the prognostic value of tumor-infiltrating lymphocyte (TIL) density as determined by molecular subtype and receipt of adjuvant chemotherapy in invasive breast cancer (IBC). METHODS: Stromal TIL densities were evaluated in 1489 IBC samples using recommendations proposed by the International TILs Working Group. Cases were allocated to high- and low-TIL density groups using a cutoff of 10%. RESULTS: Of the 1489 IBC patients, 427 (28.7%) were assigned to the high-TIL group and 1062 (71.3%) to the low-TIL group. High TIL density was found to be significantly associated with large tumor size (p = 0.001), high histologic grade (p < 0.001), and high Ki-67 labeling index (p < 0.001). Triple-negative and humanepidermal growth factor receptor 2 (HER2)-positive subtypes had significantly higher TIL densities than luminal A or B (HER2-negative) subtypes (p < 0.001). High TIL density was significantly associated with prolonged disease-free survival (DFS) by univariate (p < 0.001) and multivariate (p < 0.001) analyses. In the low-TIL-density group, the patients who did not receive adjuvant chemotherapy showed better DFS (p < 0.001), but no such survival difference was observed in the high-TIL group (p = 0.222). For the patients who received adjuvant anthracycline, high-TIL density was found to be an independent prognostic factor of favorable DFS in the luminal B (HER2-negative; p = 0.003), HER2-positive (p = 0.019), and triple-negative (p = 0.017) subtypes. CONCLUSION: Measurements of TIL density in routine clinical practice could give useful prognostic information for the triple-negative, HER2-positive, and luminal B (HER2-negative) IBC subtypes, especially for patients administered adjuvant anthracycline.
Authors: Anish A Butala; Varsha Jain; Vishruth K Reddy; Ronnie A Sebro; Yun Song; Giorgos Karakousis; Tara C Mitchell; J Nicholas Lukens; Jacob E Shabason Journal: Oncologist Date: 2020-09-17
Authors: An Sen Tan; Joe Poe Sheng Yeong; Chi Peng Timothy Lai; Chong Hui Clara Ong; Bernett Lee; Jeffrey Chun Tatt Lim; Aye Aye Thike; Jabed Iqbal; Rebecca Alexandra Dent; Elaine Hsuen Lim; Puay Hoon Tan Journal: Virchows Arch Date: 2019-08-12 Impact factor: 4.064
Authors: Rashmi Verma; Andrew M Hanby; Kieran Horgan; Eldo T Verghese; Milene Volpato; Clive R Carter; Thomas A Hughes Journal: Breast Cancer Res Treat Date: 2020-06-23 Impact factor: 4.872
Authors: Niclas C Blessin; Patrick Spriestersbach; Wenchao Li; Tim Mandelkow; David Dum; Ronald Simon; Claudia Hube-Magg; Florian Lutz; Florian Viehweger; Maximillian Lennartz; Christoph Fraune; Vera Nickelsen; Wilfried Fehrle; Cosima Göbel; Sören Weidemann; Till Clauditz; Patrick Lebok; Katharina Möller; Stefan Steurer; Jacob R Izbicki; Guido Sauter; Sarah Minner; Frank Jacobsen; Andreas M Luebke; Franziska Büscheck; Doris Höflmayer; Waldemar Wilczak; Eike Burandt; Andrea Hinsch Journal: Cell Oncol (Dordr) Date: 2020-03-05 Impact factor: 6.730